AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04555044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: Standard-of-Care Soybean Oil-Based Lipid Emulsion. 20% (lipid injectable emulsion, USP)
Study NCT05381701 — intervention group
Intervention type: PROCEDURE
Intervention: Lung Ultrasound Score
Description: Measuring the atelectasis area by ultrasound guidance from 12 different regions of the lung
Study NCT05701592 — intervention group
Intervention type: PROCEDURE
Intervention: DB-PCLR
Description: DB-PCLR with reconstruction of both PCL bundles: anterolateral and posteromedial bundle will be performed.
Study NCT04272073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Protein Mediterranean Diet
Description: As in arm/group descriptions
Study NCT04272073 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: As in arm/group descriptions
Study NCT04272073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Dietary Advice
Description: As in arm/group descriptions
Study NCT04272073 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Cardiac Rehabilitation Exercise
Description: As in arm/group descriptions
Study NCT06113939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: airway clearance
Description: mechanical suctioning of airway secretions
Study NCT06113939 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airway clearance
Description: mechanical suctioning of airway secretions
Study NCT05610696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low impact immersion
Description: Consists of a sequence of shoulder, trunk and hip movements. In this modality, the aim will be to understand the physiological effects of immersion in heat water. Resisted movements (either by turbulence or by floats) or interventional maneuvers in the knee joints will not be performed. Considering the period of 5 minutes for acclimatization to the liquid environment, the program will last approximately 47 minutes.
Study NCT05610696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional aquatic physiotherapy
Description: include warm-up, strengthening and calming down activities. Aquatic steppes will be used to ensure that all participants will maintain the waterline level approximately in the xiphoid appendix. For strengthening activities, the exercises must be performed at an adequate speed, which ensures a comfortable level for the activity. For this purpose, a subjective feedback will be extracted from the participants constantly. The warm-up sequence consists of six different active hip and knee movements performed at maximum range of motion and contributes to neuromuscular activation. For strengthening, each movement should be performed for 1 minute (30 seconds for each lower limb) followed by a period of 30 seconds of rest between each movement.
Study NCT05610696 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity aquatic physiotherapy
Description: In this modality subjects will perform the same sequence of exercises of the Conventional Aquatic Physiotherapy program will be respected. However the work load and speed will be adjusted to the maximum level. For strengthening, each movement should be performed for 2 minutes (1 minute for each lower limb) followed by a period of 30 seconds of rest between each movement. To guarantee the maximum effort of the participants, verbal stimuli will be constantly provided. The program will last approximately 68 minutes.
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAD IMG-004 30mg
Description: Each participant will be randomized to receive a single oral dose of 30mg IMG-004
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAD IMG-004 100mg
Description: Each participant will be randomized to receive a single oral dose of 100mg IMG-004
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAD IMG-004 200mg
Description: Each participant will be randomized to receive a single oral dose of 200mg IMG-004
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAD IMG-004 400mg
Description: Each participant will be randomized to receive a single oral dose of 400mg IMG-004
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAD IMG-004 600mg
Description: Each participant will be randomized to receive a single oral dose of 600mg IMG-004
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAD Placebo 30mg
Description: Each participant will be randomized to receive a single oral dose of 30mg matching placebo
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAD Placebo 100mg
Description: Each participant will be randomized to receive a single oral dose of 100mg matching placebo
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAD Placebo 200mg
Description: Each participant will be randomized to receive a single oral dose of 200mg matching placebo
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAD Placebo 400mg
Description: Each participant will be randomized to receive a single oral dose of 400mg matching placebo
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAD Placebo 600mg
Description: Each participant will be randomized to receive a single oral dose of 600mg matching placebo
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD IMG-004 50mg
Description: Each participant will be randomized to receive daily oral dose of 50mg IMG-004 for 10 days
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAD Placebo 50mg
Description: Each participant will be randomized to receive daily oral dose of 50mg matching placebo for 10 days
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD IMG-004 150mg
Description: Each participant will be randomized to receive daily oral dose of 150mg IMG-004 for 10 days
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAD Placebo 150mg
Description: Each participant will be randomized to receive daily oral dose of 150mg matching placebo for 10 days
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAD IMG-004 300mg
Description: Each participant will be randomized to receive daily oral dose of 300mg IMG-004 for 10 days
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAD Placebo 300mg
Description: Each participant will be randomized to receive daily oral dose of 300mg matching placebo for 10 days
Study NCT05349097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE IMG-004 150mg
Description: A single dose of IMG-004 at 150 mg dose level will be administered to the participants in fed and fasted states
Study NCT04731610 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Radiotherapy
Description: postoperative radiotherapy after complete resection of thymoma
Study NCT04731610 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Surveillance after resection
Description: Surveillance after tumour resection
Study NCT05541263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: The intervention used is an MBSR training which is based on the Mindfulness-Based Stress Reduction programme as developed by Kabat-Zinn (1982). The training consists of 8 weekly sessions lasting 2,5 hours. A silent day of approximately 6 hours is also included, as well as daily home practice assignments of about 45 minutes. During the training participants will learn to focus their attention in the present moment in an accepting and non-judgemental way, rather than ruminating about past and future experiences. The training includes formal exercises during which participants will practice the body scan, sitting meditation, walking meditation and mindful movement. Informal exercises are also included, such as performing a daily activity with full attention to the present experience. The training is led by qualified teachers meeting the advanced criteria of the Association of Mindfulness Based Teachers in the Netherlands and Flanders (www.vmbn.nl)
Study NCT05073601 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA,DNA extraction
Description: quantitative measurement of (Thyroid stimulating hormon (TSH), free triiodothyronine (FT3)\& Free tetraiodothyronine(FT4)) measured using ELISA . Serum 25-OH vitamin D measured using ELISA. Serum 25-OH vitamin D will be classified based on 2012 American Endocrine Society guidelines into deficient (\< 20ng/ml), insufficient ( 21 -30 ng/ml) and sufficient (> 30 ng/ml).vitamin D receptor polymorphisms was done in 3 steps: a) DNA extraction from whole blood using Gene Jet gene DNA Purification kits . b) PCR: three Vitamin D receptor polymorphisms were tested \[Taq I (restriction enzymes according to single nucleotide polymorphism ) (rs731236), Apa I (rs7975232) and Bsm I (rs1544410)\] using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Genomic DNA was amplified using certain primers
Study NCT05717686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHB-137 injection
Description: AHB-137 will be administered
Study NCT05717686 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered
Study NCT05187767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: cf DNA and ct DNA
Description: Quantification of the circulating free DNA and the presence of targeted circulating tumor DNA
Study NCT06308367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Description: 50mg/kg for 12 weeks
Study NCT06308367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04921423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Situational simulation teaching
Description: The intervention included communication theory and skills, aging trend and knowledge, teaching plans for elderly nursing, activities for the elderly and visual experience, application and debriefing of empathy.
Study NCT05200650 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TumoCure
Description: TumoCure is a polymer-based gel, loaded with Cisplatin in a dose of 100mg (10% w/w), injected to head and neck tumors locally in a single injection.
Study NCT04792853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tab-G
Description: Participants receive a tablet preloaded with Tab-G application and an accelerometer.
Study NCT05706493 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non surgical periodontal treatment
Description: Non-surgical periodontal treatment will be performed using ultrasonic scaler and subgingival curettes
Study NCT06164249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strength training
Description: Strength training, three times a week, during nine weeks.
Study NCT06505824 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M14D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT04768920 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI-CBT Teletx
Description: Participants will first receive a 20-45 min phone or video session focused on raising participants' motivation to engage in treatment activities and psychoeducation material about substance use (i.e. engagement session) including possible discussion about risks of substance use, value of alternative healthier activities, and the community and crisis resources pamphlet. The evidence-based manualized psychosocial programs that will be delivered via telehealth are adaptations of cognitive behavioral therapy, motivational interviewing, and other psychosocial interventions to enhance initial and ongoing treatment engagement. TeleTx consists of up to 8 \~30-50 minute psychosocial sessions delivered via phone or videoconference platform (e.g. Zoom etc)
Study NCT04963621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Child-Adolescent Emotion and Stress Intervention Program
Description: Intervention programs include Emotion and Stress Intervention for children with emotional and stress problems
Study NCT04963621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Child-Adolescent Emotion and Stress Intervention Program
Description: Intervention programs include Emotion and Stress Intervention for children with emotional and stress problems
Study NCT05893303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1st Group
Description: 1st group is going to undergo scapula-oriented PNF techniques (diagonal) which are anterior elevation and posterior depression - posterior elevation and anterior depression with 20 repetitions with rhythmic initiation and repeated contractions facilitation techniques during all patterns. In addition to PNF techniques, gait training is going to be applied as standing with balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
Study NCT05893303 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2nd Group
Description: 2nd group is going to undergo only gait training and balance exercises (15 repetitions) as well as specific exercises for the stance and swing phases of the gait which are; stepping forward and sideways (15 repetitions), and gait education (walking 3 lapses within 2 meters parallel bar)
Study NCT06200636 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the PELSA System for dISF extraction
Description: Dermal interstitial fluid will be extracted using the investigational device, for further analysis.
Study NCT05815368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REMO
Description: REMO training will consist of sEMG-biofeedback exercises provided by REMO device. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
Study NCT06434493 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthotropic Liver Transplant
Description: If still eligible after neoadjuvant treatment (PBT + capecitabine), patients will be added to the liver transplant waiting list.
Study NCT05264454 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: high flow nasal cannulae
Description: The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
Study NCT05264454 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high flow nasal cannulae
Description: The plan is to examine the effects of the size of the IVC size based upon varrying levels of high flow nasal cannulae flow
Study NCT04609046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration and Biopsy
Description: Undergo bone marrow aspirate and biopsy
Study NCT04609046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT and PET/CT
Study NCT04609046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT05485779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQ280
Description: Dose form: capsule, hard~Strength: 3 to 100 mg~Method of administration: oral
Study NCT04609046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT05686889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient self-report
Description: Simulated patient following structured script
Study NCT05714059 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insulin Pump with Continuous Glucose Monitoring
Description: MiniMed™ 780G insulin pump in combination with the DS5 CGM
Study NCT04609046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT04609046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT04609046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV or PO
Study NCT04609046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT04609046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04609046 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT04609046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo testicular ultrasound
Study NCT05694494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: internet-based Lifestyle-integrated Functional Exercise (iLiFE)
Description: receiving internet-based LiFE training and home safety assessment
Study NCT05694494 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: upper limb exercise training
Description: upper limb exercise training
Study NCT05815368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task-Oriented Training
Description: Task-Oriented training will consist of task-specific functional exercises. The training will be provided 1 hour a day, for 5 days/week, for totally 3 weeks.
Study NCT04998513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Management Alone Arm
Description: The medical intervention consists of intravenous dexamethasone (10 mg if bodyweight \< 70 kilograms, 20 mg if bodyweight > 70 kilograms), intravenous cefazolin 2 grams, intravenous metronidazole 500 mg, oral probenecid 2 grams, and 1 liter of intravenous crystalloid fluid given over 1 hour.~If, during the initial post-enrolment day 1 follow-up, patients report a failure of signs and symptoms to improve since their medical therapy, a second round of intravenous crystalloid fluid, cefazolin, probenecid, metronidazole and dexamethasone will be given at the same dose as the initial medical therapy. Failure to improve patient signs and symptoms over a two-hour observation window will prompt surgical intervention to be performed in the same fashion as the surgical intervention group.
Study NCT04998513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Arm
Description: Surgical intervention consists of attempted incision and drainage of the abscess. Specific procedure steps and details are at the discretion of the treating surgeon. In general, incision and drainage consists of topical and submucosal local anesthetic followed by a mucosal incision along the palatoglossal arch and soft palate junction, and blunt dissection of the abscess cavity to evacuate pus. Some surgeons may first perform a needle aspiration. For purposes of the trial, positive aspiration of pus on needle aspiration must be followed by attempted incision and drainage. Failed needle aspiration or surgical drainage will be considered as a failed attempt at surgical intervention.~Patients randomized to receive surgical intervention will also receive medications as per the medical management arm.
Study NCT06560788 — intervention group
Intervention type: OTHER
Intervention: collection of cerebrospinal fluid
Description: CSF is collected as part of routine care in any of the surgeries listed in the control or cases groups. We will take part of that CSF for proteomic analysis
Study NCT05485779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Active substance: none~Dose form: capsule, hard~Strength/dose: not applicable~Method of administration: oral
Study NCT04868565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
Description: after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight.
Study NCT04868565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT]
Description: after randomization, caffeine citrate will be contineously prescribed to those patients assigned to the ongoing caffeine with oxygen supplement (group 2) with a medication regimen of 10mg/kg.dose, once daily, and weekly adjustment based on the working weight.
Study NCT04742075 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olaparib + durvalumab + UV1
Description: The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
Study NCT04878237 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Secretion Sampling
Description: Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)
Study NCT04878237 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Secretion Sampling
Description: Nasal specimen collection will be performed at all visits. For every visit specimens will be collected using nasosorption FXi/PU (containing a synthetic absorptive matrix (SAM)), or a 10 cm-long plastic curette (nasosorption devices from Hunt Developments, UK) (Curette devices from Arlington Scientific, USA)
Study NCT04917627 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: one vial of vancomycin (1000 mg ) powder form.
Study NCT04742075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib + durvalumab + UV1
Description: The subjects are randomized 1:1:2 to receive treatment until progression of disease or untorable toxicity.
Study NCT04789083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propholis extrate
Description: Plassebo